Analysed Regen Biopharma Inc (RGBPP:OTCMKTS) News Sources
Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
24-02-2026
yahoo.com
Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
20-01-2026
yahoo.com
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
09-12-2025
yahoo.com
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
05-11-2025
yahoo.com
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
22-10-2025
yahoo.com
Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025
23-09-2025
yahoo.com
Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream
23-09-2025
yahoo.com
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate
16-09-2025
yahoo.com
Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression
04-09-2025
yahoo.com
What is the current price of Regen Biopharma Inc (RGBPP:OTCMKTS)?
The current price of Regen Biopharma Inc (RGBPP:OTCMKTS) is $0.0031.
Regen Biopharma Inc (RGBPP:OTCMKTS) absolute price change since previous trading day?
The absolute price change of Regen Biopharma Inc (RGBPP:OTCMKTS) since the previous trading day is $-0.00144.
Regen Biopharma Inc (RGBPP:OTCMKTS) percentage price change since previous trading day?
The percentage price change of Regen Biopharma Inc (RGBPP:OTCMKTS) since the previous trading day is -31.7181%.
What is the most recent average sentiment score for Regen Biopharma Inc (RGBPP:OTCMKTS)?
The most recent average sentiment score for Regen Biopharma Inc (RGBPP:OTCMKTS) is 80 out of 100.
What is the most recent average sentiment for Regen Biopharma Inc (RGBPP:OTCMKTS)?
The most recent sentiment for Regen Biopharma Inc (RGBPP:OTCMKTS) is .
SEC-8K** Filing Available For Regen Biopharma Inc (RGBPP:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.